Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137

Benzinga Newsdesk www.benzinga.com Negative 95.0%

Neg 95% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers the price target from $146 to $137.